Navigation Links
Dallas Cardiologists Explore 'Next Frontier' in Vascular-Disease Treatments
Date:9/24/2008

DALLAS, Sept. 24 /PRNewswire-USNewswire/ -- Presbyterian Hospital of Dallas is one of only a handful of medical centers in the United States -- and the only Texas facility -- to broadcast live interventional cases to the prestigious Vascular InterVentional Advances conference, held this week in Las Vegas, Nev.

The VIVA conference will educate over 1,000 physicians and medical personnel on the latest advances in the treatment of peripheral vascular disease (PVD), a looming health crisis as the U.S. population ages and more Americans battle obesity.

Drs. Tony Das and James Park, interventional cardiologists at Presbyterian Hospital of Dallas, will perform cases from Presbyterian's cardiac catheterization lab. The procedures will be transmitted in high-definition to the conference in Las Vegas, where cardiac experts from around the world will be assembled.

"With the prevalence of diabetes and obesity among an already aging population, the challenges facing those involved in the diagnosis and treatment of peripheral vascular disease are overwhelming," Dr. Das said. "It's a problem that will increasingly challenge medical experts around the country in coming years."

Other sites for live cases include The Cleveland Clinic and the University of California Davis Medical Center.

PVD is a common condition affecting more than 10 million adults in the United States. The condition is a disease of blood vessels outside the heart and brain characterized by a narrowing of vessels that carry blood to the legs, arms, stomach and kidney.

The live cases from Presbyterian will demonstrate complex vascular procedures to open and stent arteries supplying the kidneys, focusing part of their session on the increase in renal artery disease in the United States. Other cases will focus on techniques to open complex blockages of the femoral and tibial arteries, which supply blood to the lower limbs. If untreated, the condition can lead to tissue
'/>"/>

SOURCE Texas Health Resources
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Allergists at Presbyterian Hospital of Dallas Say This Years Fall Allergy Season Could be Worst in Decades
2. Northstar Healthcare Announces Option to Purchase a 60% Interest in The Palladium for Surgery - Dallas
3. Dallas-Area Transplant Meeting Puts Spotlight on Key Issues
4. MilkPEP: Dallas Area Family Wins Nationwide got milk? Contest
5. Dallas Among the First to Offer Probiotic Supplement Align(R)
6. ViewPoint Bank Funds Senior Crimestoppers Program at Meadows Health and Rehab Center in Dallas
7. Dallas-Fort Worth Business Group on Health Releases Report on the State of Diabetes in Texas
8. OrthoSynetics(TM) Opens Regional Offices in Dallas, Atlanta
9. Susan G. Komen for the Cure Sharing Grassroots Advocacy Knowledge With International Representatives in Intensive Dallas Training Session
10. More Women File Lawsuits Against Dallas Presbyterian Hospital in Eating Disorders Fraud Case
11. Crdentia Promotes Kevin Bollin to Area Manager of Austin, Dallas and San Antonio, Texas, Markets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... (Boston)-- Researchers from Boston University School of Medicine ... that participants who received care through BMC,s Violence ... physical, mental, emotional and social needs of violently ... injuries and experienced life changing behaviors through connections ... feel trust and hope. These findings are reported ...
(Date:7/22/2014)... The European Bio stimulants Market report defines ... analysis and forecast of revenue. The bio stimulants market ... million in 2013 to $940.6 million by 2018, at ... Browse through the TOC of the Europe Bio stimulants ... analysis provided. , http://www.micromarketmonitor.com/market/europe-bio-stimulants-1315565884.html , Agriculture contributes ...
(Date:7/22/2014)... California (PRWEB) July 22, 2014 In ... women in recovery, the Marinello School of Beauty joined ... Addiction Treatment Center for a free “Make-over Day.” ... to be of service to the community, and The ... and renewed. They also gained some first-hand experience about ...
(Date:7/22/2014)... 2014 Expert Publishing ... , announces the launch of PoisonEXPERT™ , ... safety professionals employed by organizations that use or ... manage the impact of chemicals on their employees ... relevant chemical-specific information and medical protocols that allows ...
(Date:7/22/2014)... Transparency Market Research has announced the ... Diagnostics Market – Global Industry Analysis, Size, Share, Growth, ... comprehensive database. This industry is considered as the most ... valued at USD 8.7 billion by 2019 and expected ... to 2019. Molecular diagnostics is the class of diagnostic ...
Breaking Medicine News(10 mins):Health News:Clients of BMC's violence interventional advocacy program find experience supportive 2Health News:Clients of BMC's violence interventional advocacy program find experience supportive 3Health News:Europe Bio Stimulants Market is Expected to Reach $940.6 Million in 2018 - New Report by MicroMarket Monitor 2Health News:Europe Bio Stimulants Market is Expected to Reach $940.6 Million in 2018 - New Report by MicroMarket Monitor 3Health News:Europe Bio Stimulants Market is Expected to Reach $940.6 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Europe Bio Stimulants Market is Expected to Reach $940.6 Million in 2018 - New Report by MicroMarket Monitor 5Health News:The Discovery House 'Make-over Day' Adds Pampering To Recovery 2Health News:The Discovery House 'Make-over Day' Adds Pampering To Recovery 3Health News:PoisonEXPERT™ from ExPub Now Available 2Health News:PoisonEXPERT™ from ExPub Now Available 3Health News:Global Molecular Diagnostics Market Expected to Reach USD 8.7 Billion through 2019: Transparency Market Research 2Health News:Global Molecular Diagnostics Market Expected to Reach USD 8.7 Billion through 2019: Transparency Market Research 3Health News:Global Molecular Diagnostics Market Expected to Reach USD 8.7 Billion through 2019: Transparency Market Research 4
... a Diet High in Fruits and Vegetables ,Healthy Foods ... patients with kidney disease, the Western diet produces an acidic ... worsens with age as kidney function declines. Nimirit Goraya, MD ... and her colleagues conducted a study to see if consuming ...
... By Ellin Holohan HealthDay Reporter , FRIDAY, ... against alcohol use, can relax and have a drink a ... weight, two new Dutch studies show. The researchers found ... be unfounded, while concerns about weight are not. Both ...
... 19 (HealthDay News) -- A new, small study suggests that the ... dose of tamoxifen, a drug commonly used to prevent and treat ... cough medicine at about the same rate as tamoxifen, allowing doctors ... drug. "This study is starting to identify a personalized ...
... NEW YORK (Nov. 20, 2010) Columbia University Medical ... a Harvard researcher who has made important advances in ... and heart disease. A promising young investigator at Columbia ... the basis for disordered lipid metabolism in diabetes. ...
... By Madonna Behen HealthDay Reporter , FRIDAY, Nov. ... on U.S. college campuses, college officials are trying various ways ... targeted off-campus boozing shows some promise, researchers say. ... cut the level of heavy drinking at private parties and ...
... 19, 2010 University of Houston (UH) physicists are ... a crucial protein that, when malfunctioning, may cause Alzheimer,s ... physics at UH, and Antonios Samiotakis, a physics Ph.D. ... function, and folding of phosphoglycerate kinase (PGK) are strongly ...
Cached Medicine News:Health News:Kidneys: Produce-rich diet improves long-term health, melatonin improves short-term health 2Health News:Kidneys: Produce-rich diet improves long-term health, melatonin improves short-term health 3Health News:Moderate Drinking Could Lower Death Risk for Kidney Transplant Patients 2Health News:Moderate Drinking Could Lower Death Risk for Kidney Transplant Patients 3Health News:Moderate Drinking Could Lower Death Risk for Kidney Transplant Patients 4Health News:Cough Syrup Might Help With Dosing of Breast Cancer Drug 2Health News:Harvard expert on inflammation's role in obesity receives Columbia's 2010 Naomi Berrie Award 2Health News:Harvard expert on inflammation's role in obesity receives Columbia's 2010 Naomi Berrie Award 3Health News:Harvard expert on inflammation's role in obesity receives Columbia's 2010 Naomi Berrie Award 4Health News:Outreach, Enforcement Can Curb College Kids' Drinking: Study 2Health News:Outreach, Enforcement Can Curb College Kids' Drinking: Study 3Health News:UH physicists study behavior of enzyme linked to Alzheimer's, cancer 2Health News:UH physicists study behavior of enzyme linked to Alzheimer's, cancer 3
(Date:7/22/2014)... July 22, 2014 According ... "Process Spectroscopy Market (Technology Types - Near infrared (NIR) spectroscopy, ... Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 ... in 2012 and is expected to grow at a CAGR ... North America was the largest contributor to global ...
(Date:7/22/2014)... MOUNTAIN VIEW, Calif. , July 22, 2014 ... magnetic resonance imaging (MRI) market, Frost & Sullivan ... Award for Product Leadership. Siemens Healthcare,s FREEZEit solution, ... addresses the need for robust and motion-insensitive imaging. ... has boosted the evolution of body MRI imaging ...
(Date:7/22/2014)... , July 22, 2014  Halozyme Therapeutics, Inc. ... has resumed enrollment and dosing of patients in its ... patients with pancreatic cancer under the revised clinical protocol ... an investigational PEGylated form of Halozyme,s proprietary recombinant human ... that accumulate hyaluronan. "Our diligent effort ...
Breaking Medicine Technology:Process Spectroscopy Market Expected to Reach USD 1,179.6 Million in 2019: Transparency Market Research 2Process Spectroscopy Market Expected to Reach USD 1,179.6 Million in 2019: Transparency Market Research 3Process Spectroscopy Market Expected to Reach USD 1,179.6 Million in 2019: Transparency Market Research 4Frost & Sullivan Recognizes Siemens Healthcare with the Product Leadership Award for Innovative Techniques in Abdominal Imaging 2Frost & Sullivan Recognizes Siemens Healthcare with the Product Leadership Award for Innovative Techniques in Abdominal Imaging 3Frost & Sullivan Recognizes Siemens Healthcare with the Product Leadership Award for Innovative Techniques in Abdominal Imaging 4Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Program In Pancreatic Cancer 2Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Program In Pancreatic Cancer 3
... 2011 Techne Corporation,s (NASDAQ: TECH ) financial ... 30, 2011 include the following highlights: , ... per diluted share.  Earnings for the quarter grew 21.2% to ... intangible asset amortization, costs recognized upon the sale of inventory ...
... 2, 2011 MAP Pharmaceuticals, Inc. (Nasdaq: MAPP ... LEVADEX® orally inhaled migraine drug for the potential acute treatment ... the U.S. Food and Drug Administration (FDA), with a goal ... Fee Act (PDUFA). In accordance with the Company,s collaboration agreement ...
Cached Medicine Technology:Techne Corporation Releases Unaudited Fourth Quarter and Fiscal Year 2011 Results 2Techne Corporation Releases Unaudited Fourth Quarter and Fiscal Year 2011 Results 3Techne Corporation Releases Unaudited Fourth Quarter and Fiscal Year 2011 Results 4Techne Corporation Releases Unaudited Fourth Quarter and Fiscal Year 2011 Results 5Techne Corporation Releases Unaudited Fourth Quarter and Fiscal Year 2011 Results 6Techne Corporation Releases Unaudited Fourth Quarter and Fiscal Year 2011 Results 7Techne Corporation Releases Unaudited Fourth Quarter and Fiscal Year 2011 Results 8Techne Corporation Releases Unaudited Fourth Quarter and Fiscal Year 2011 Results 9Techne Corporation Releases Unaudited Fourth Quarter and Fiscal Year 2011 Results 10Techne Corporation Releases Unaudited Fourth Quarter and Fiscal Year 2011 Results 11MAP Pharmaceuticals Announces FDA Acceptance for Filing of NDA for LEVADEX® 2MAP Pharmaceuticals Announces FDA Acceptance for Filing of NDA for LEVADEX® 3MAP Pharmaceuticals Announces FDA Acceptance for Filing of NDA for LEVADEX® 4